期刊文献+

DPP-4与氰基吡咯烷类抑制剂相互作用的分子动力学模拟 被引量:2

Molecular dynamics simulation of binding of cyanopyrrolidine inhibitors to dipeptidyl peptidase-4( DPP-4)
下载PDF
导出
摘要 通过分子对接、分子动力学(MD)模拟和自由能分析的方法研究3种氰基吡咯烷抑制剂与二肽基肽酶-4(DPP-4)之间的成键机制,分析和讨论3种抑制剂与二肽基肽酶之间的静电相互作用、范德华相互作用。用MM-PBSA方法计算得到的3种抑制剂的结合自由能与实验测得的结果是一致的。抑制剂与残基所形成的氢键能够使抑制剂稳定在结合位点。由残基Tyr631和Tyr666与抑制剂形成的范德华相互作用对结合自由能起到关键作用,并且显著地将3种不同抑制剂的生物活性区分开来。 The binding nechanism between three cyanopyrrolidine inhibitors and DPP-4 was investigated by molecular docking,molecular dynamics (MD) simulation and binding free energy analysis.The electrostatic and van der Waals interactions of the three inhibitors with DPP-4 were analyzed and discussed.The computed binding free energies using MM-PBSA method were in qualitatively agreement with experimental inhibitory potency of three inhibitors.The hydrogen bonds of inhibitors could stabilize the inhibitors in binding sites.The van der Waals interactions,between the inhibitors and residue Tyr631 and Tyr666 showed the key contributions to the binding free energy and played an important role in distinguishing the variant bioactivity of three inhibitors.
出处 《南京工业大学学报(自然科学版)》 CAS 北大核心 2015年第3期120-124,共5页 Journal of Nanjing Tech University(Natural Science Edition)
基金 国家自然科学基金(21276122 21136001 20876073)
关键词 分子动力学模拟 MM-PBSA方法 二肽基肽酶-4 氰基吡咯烷抑制剂 molecular dynamics simulation MM-PBSA method DPP-4 cyanopyrrolidine inhibitor
  • 相关文献

参考文献14

  • 1Stephen W,Mark J.Cis-2,5-dicyanopyrrolidine inhibitors of dipeptidyl peptidase IV:synthesis and in vitro,in vivo,and X-ray crystallographic characterization[J].Med Chem,2006,49:3068-3076.
  • 2Nielsen L L.Incretin minetics and DPP-4 inhibitors for the treatment of type 2 diabetes[J].Drug Discov Today,2005,10(10):703-710.
  • 3Nauck M A,Niedereichholz U,Ettler R,et al.Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulino-tropic effects in healthy humans[J].Am J Physiol,1997,273:E981-E988.
  • 4Flint A,Raben A,Ersboll A K,et al.The effect of physiological levels of glucagons-like peptide-1 on appetite,gastric emptying,energy and substrate metabolism in obesity[J].Int J Obes Relat Metab Disord,2001,25:781-792.
  • 5Ahren B.DPP-4 inhibitors[J].Best Prac Res Clin Endocrinol Metab,2007,21(4):517-533.
  • 6Augeri D J,Robl J A,Betebenner D A,et al.Discovery and preclinical profile of saxagliptin(BMS-477118):a highly potent,long-acting,orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes[J].J Med Chem,2005,48(15):5025-5037.
  • 7Villhauer E B,Brinkman J A,Naderi G B,et al.1-[[(3-hy-droxy-1-adamantyl)amino] acetyl] -2-cyano-(S)-pyrrolidine:a potent,selective,and orally bioavailable dipeptidyl peptidase IV inhibitor with antihyperglycemic properties[J].J Med Chem,2003,46(13):2774-2789.
  • 8Kim D,Wang L,Beconi M,et al.(2R)-4-oxo-4-[3-(triflu-oromethyl)-5,6-dihydro[1,2,4] triazolo[4,3-a] pyrazin-7(8H)-yl] -1-(2,4,5-trifluorophenyl)butan-2-amine:a potent,orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes[J].J Med Chem,2005,48(1):141-151.
  • 9Kuhn B,Hennig M,Mattei P.Molecular recognition of ligands in dipeptidyl peptidase IV[J].Curr Top Med Chem,2007,7(6):609-619.
  • 10Weber A E.Dipeptidyl peptidase IV inhibitors for the treatment of diabetes[J].J Med Chem,2004,47(17):4135-4141.

同被引文献24

引证文献2

二级引证文献15

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部